APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Humanized Monoclonal Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Humanized Monoclonal Antibody Drugs Market Outlook and Growth Opportunities 2026

Report ID 174000250423 December 2025207 pages

Choose your research edition.

Industry ResearchHumanized Monoclonal Antibody Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Humanized Monoclonal Antibody Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Humanized Monoclonal Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Humanized Monoclonal Antibody Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Humanized Monoclonal Antibody Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Humanized Monoclonal Antibody Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Humanized Monoclonal Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Humanized Monoclonal Antibody Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Humanized Monoclonal Antibody Drugs market include Innovent Bio, Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Qilu Pharma, Novartis, Merck & Co and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Humanized Monoclonal Antibody Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Humanized Monoclonal Antibody Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Humanized Monoclonal Antibody Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Humanized Monoclonal Antibody Drugs market.

Humanized Monoclonal Antibody Drugs Segment by Company

Innovent Bio

Takeda

Teva

Sun Pharmaceutical

Johnson & Johnson

Qilu Pharma

Novartis

Merck & Co

Roche

Eli Lilly & Co

Pfizer

Beigene

GlaxoSmithKline

Biogen

AbbVie

AstraZeneca

UCB

Gilead Sciences

Humanized Monoclonal Antibody Drugs Segment by Type

Ixekizumab

Vedolizumab

Risenqizumab

Trastuzumab

Pembrolizumab

Farisimab

Bevacizumab

Orelizumab

Omalizumab

Other

Humanized Monoclonal Antibody Drugs Segment by Application

Cancers

Inflammatory Condition

Autoimmune Diseases

Humanized Monoclonal Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Humanized Monoclonal Antibody Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Humanized Monoclonal Antibody Drugs key companies, revenue, market share, and recent developments.

3. To split the Humanized Monoclonal Antibody Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Humanized Monoclonal Antibody Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Humanized Monoclonal Antibody Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Humanized Monoclonal Antibody Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Humanized Monoclonal Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Humanized Monoclonal Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Humanized Monoclonal Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Humanized Monoclonal Antibody Drugs industry.

Chapter 3: Detailed analysis of Humanized Monoclonal Antibody Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Humanized Monoclonal Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Humanized Monoclonal Antibody Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Humanized Monoclonal Antibody Drugs Industry Trends Table 2. Humanized Monoclonal Antibody Drugs Industry Drivers Table 3. Humanized Monoclonal Antibody Drugs Industry Opportunities and Challenges Table 4. Humanized Monoclonal Antibody Drugs Industry Restraints Table 5. Global Humanized Monoclonal Antibody Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Humanized Monoclonal Antibody Drugs Revenue Share by Company (2021-2026) Table 7. Global Humanized Monoclonal Antibody Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Humanized Monoclonal Antibody Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Humanized Monoclonal Antibody Drugs Company, Product Type & Application Table 10. Global Humanized Monoclonal Antibody Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Humanized Monoclonal Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ixekizumab Table 15. Significant Companies of Vedolizumab Table 16. Significant Companies of Risenqizumab Table 17. Significant Companies of Trastuzumab Table 18. Significant Companies of Pembrolizumab Table 19. Significant Companies of Farisimab Table 20. Significant Companies of Bevacizumab Table 21. Significant Companies of Orelizumab Table 22. Significant Companies of Omalizumab Table 23. Significant Companies of Other Table 24. Global Humanized Monoclonal Antibody Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Humanized Monoclonal Antibody Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Humanized Monoclonal Antibody Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Type (2021-2026) Table 28. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Cancers Table 30. Significant Companies of Inflammatory Condition Table 31. Significant Companies of Autoimmune Diseases Table 32. Global Humanized Monoclonal Antibody Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Humanized Monoclonal Antibody Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 34. Global Humanized Monoclonal Antibody Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 35. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Application (2021-2026) Table 36. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Application (2027-2032) Table 37. Global Humanized Monoclonal Antibody Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Humanized Monoclonal Antibody Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 39. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Region (2021-2026) Table 40. Global Humanized Monoclonal Antibody Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 41. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Region (2027-2032) Table 42. Global Humanized Monoclonal Antibody Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Humanized Monoclonal Antibody Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 44. Global Humanized Monoclonal Antibody Drugs Sales Value Market Share by Country (2021-2026) Table 45. Global Humanized Monoclonal Antibody Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 46. Global Humanized Monoclonal Antibody Drugs Sales Value Market Share by Country (2027-2032) Table 47. Innovent Bio Company Information Table 48. Innovent Bio Business Overview Table 49. Innovent Bio Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Innovent Bio Humanized Monoclonal Antibody Drugs Product Portfolio Table 51. Innovent Bio Recent Development Table 52. Takeda Company Information Table 53. Takeda Business Overview Table 54. Takeda Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Takeda Humanized Monoclonal Antibody Drugs Product Portfolio Table 56. Takeda Recent Development Table 57. Teva Company Information Table 58. Teva Business Overview Table 59. Teva Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Teva Humanized Monoclonal Antibody Drugs Product Portfolio Table 61. Teva Recent Development Table 62. Sun Pharmaceutical Company Information Table 63. Sun Pharmaceutical Business Overview Table 64. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product Portfolio Table 66. Sun Pharmaceutical Recent Development Table 67. Johnson & Johnson Company Information Table 68. Johnson & Johnson Business Overview Table 69. Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Johnson & Johnson Humanized Monoclonal Antibody Drugs Product Portfolio Table 71. Johnson & Johnson Recent Development Table 72. Qilu Pharma Company Information Table 73. Qilu Pharma Business Overview Table 74. Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Qilu Pharma Humanized Monoclonal Antibody Drugs Product Portfolio Table 76. Qilu Pharma Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Novartis Humanized Monoclonal Antibody Drugs Product Portfolio Table 81. Novartis Recent Development Table 82. Merck & Co Company Information Table 83. Merck & Co Business Overview Table 84. Merck & Co Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Merck & Co Humanized Monoclonal Antibody Drugs Product Portfolio Table 86. Merck & Co Recent Development Table 87. Roche Company Information Table 88. Roche Business Overview Table 89. Roche Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Roche Humanized Monoclonal Antibody Drugs Product Portfolio Table 91. Roche Recent Development Table 92. Eli Lilly & Co Company Information Table 93. Eli Lilly & Co Business Overview Table 94. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product Portfolio Table 96. Eli Lilly & Co Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Pfizer Humanized Monoclonal Antibody Drugs Product Portfolio Table 101. Pfizer Recent Development Table 102. Beigene Company Information Table 103. Beigene Business Overview Table 104. Beigene Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Beigene Humanized Monoclonal Antibody Drugs Product Portfolio Table 106. Beigene Recent Development Table 107. GlaxoSmithKline Company Information Table 108. GlaxoSmithKline Business Overview Table 109. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product Portfolio Table 111. GlaxoSmithKline Recent Development Table 112. Biogen Company Information Table 113. Biogen Business Overview Table 114. Biogen Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Biogen Humanized Monoclonal Antibody Drugs Product Portfolio Table 116. Biogen Recent Development Table 117. AbbVie Company Information Table 118. AbbVie Business Overview Table 119. AbbVie Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. AbbVie Humanized Monoclonal Antibody Drugs Product Portfolio Table 121. AbbVie Recent Development Table 122. AstraZeneca Company Information Table 123. AstraZeneca Business Overview Table 124. AstraZeneca Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. AstraZeneca Humanized Monoclonal Antibody Drugs Product Portfolio Table 126. AstraZeneca Recent Development Table 127. UCB Company Information Table 128. UCB Business Overview Table 129. UCB Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. UCB Humanized Monoclonal Antibody Drugs Product Portfolio Table 131. UCB Recent Development Table 132. Gilead Sciences Company Information Table 133. Gilead Sciences Business Overview Table 134. Gilead Sciences Humanized Monoclonal Antibody Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Gilead Sciences Humanized Monoclonal Antibody Drugs Product Portfolio Table 136. Gilead Sciences Recent Development Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Humanized Monoclonal Antibody Drugs Product Image Figure 2. Global Humanized Monoclonal Antibody Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Humanized Monoclonal Antibody Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Humanized Monoclonal Antibody Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ixekizumab Image Figure 8. Vedolizumab Image Figure 9. Risenqizumab Image Figure 10. Trastuzumab Image Figure 11. Pembrolizumab Image Figure 12. Farisimab Image Figure 13. Bevacizumab Image Figure 14. Orelizumab Image Figure 15. Omalizumab Image Figure 16. Other Image Figure 17. Global Humanized Monoclonal Antibody Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Humanized Monoclonal Antibody Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Type (2021-2032) Figure 20. Cancers Image Figure 21. Inflammatory Condition Image Figure 22. Autoimmune Diseases Image Figure 23. Global Humanized Monoclonal Antibody Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Humanized Monoclonal Antibody Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Humanized Monoclonal Antibody Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 27. Global Humanized Monoclonal Antibody Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 28. North America Humanized Monoclonal Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. North America Humanized Monoclonal Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Europe Humanized Monoclonal Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Europe Humanized Monoclonal Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Asia-Pacific Humanized Monoclonal Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Asia-Pacific Humanized Monoclonal Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. South America Humanized Monoclonal Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. South America Humanized Monoclonal Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Middle East & Africa Humanized Monoclonal Antibody Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Middle East & Africa Humanized Monoclonal Antibody Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. USA Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. USA Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. USA Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Canada Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Canada Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Canada Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Mexico Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Mexico Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Mexico Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Germany Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Germany Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Germany Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. France Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. France Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. France Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. U.K. Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. U.K. Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. U.K. Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Italy Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Italy Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Italy Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Spain Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Spain Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Spain Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Russia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Russia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Russia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Netherlands Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Netherlands Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Netherlands Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Nordic Countries Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Nordic Countries Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Nordic Countries Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. China Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. China Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. China Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Japan Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Japan Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Japan Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. South Korea Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. South Korea Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. South Korea Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. India Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. India Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. India Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Australia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Australia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Australia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Southeast Asia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Southeast Asia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Southeast Asia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Brazil Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Brazil Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Brazil Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Argentina Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Argentina Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Argentina Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Chile Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Chile Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Chile Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Colombia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Colombia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Colombia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Peru Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Peru Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Peru Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Saudi Arabia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Israel Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Israel Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Israel Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. UAE Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. UAE Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. UAE Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Turkey Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Turkey Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Turkey Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Iran Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Iran Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Iran Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Egypt Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Egypt Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Egypt Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Years Considered Figure 123. Research Process Figure 124. Key Executives Interviewed

Scope & coverage.

Types
  • Ixekizumab
  • Vedolizumab
  • Risenqizumab
  • Trastuzumab
  • Pembrolizumab
  • Farisimab
  • Bevacizumab
  • Orelizumab
  • Omalizumab
  • Other
Applications
  • Cancers
  • Inflammatory Condition
  • Autoimmune Diseases
Companies covered
  • Innovent Bio
  • Takeda
  • Teva
  • Sun Pharmaceutical
  • Johnson & Johnson
  • Qilu Pharma
  • Novartis
  • Merck & Co
  • Roche
  • Eli Lilly & Co
  • Pfizer
  • Beigene
  • GlaxoSmithKline
  • Biogen
  • AbbVie
  • AstraZeneca
  • UCB
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Humanized Monoclonal Antibody Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Humanized Monoclonal Antibody Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Humanized Monoclonal Antibody Drugs Market Dynamics
  1. 2.1 Humanized Monoclonal Antibody Drugs Industry Trends
  2. 2.2 Humanized Monoclonal Antibody Drugs Industry Drivers
  3. 2.3 Humanized Monoclonal Antibody Drugs Industry Opportunities and Challenges
  4. 2.4 Humanized Monoclonal Antibody Drugs Industry Restraints
3 Humanized Monoclonal Antibody Drugs Market by Company
  1. 3.1 Global Humanized Monoclonal Antibody Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Humanized Monoclonal Antibody Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Humanized Monoclonal Antibody Drugs Company Ranking (2024-2026)
  4. 3.4 Global Humanized Monoclonal Antibody Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Humanized Monoclonal Antibody Drugs Company Product Type and Application
  6. 3.6 Global Humanized Monoclonal Antibody Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Humanized Monoclonal Antibody Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Humanized Monoclonal Antibody Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Humanized Monoclonal Antibody Drugs Market by Type
  1. 4.1 Humanized Monoclonal Antibody Drugs Type Introduction
  2. 4.1.1 Ixekizumab
  3. 4.1.2 Vedolizumab
  4. 4.1.3 Risenqizumab
  5. 4.1.4 Trastuzumab
  6. 4.1.5 Pembrolizumab
  7. 4.1.6 Farisimab
  8. 4.1.7 Bevacizumab
  9. 4.1.8 Orelizumab
  10. 4.1.9 Omalizumab
  11. 4.1.10 Other
  12. 4.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Type
  13. 4.2.1 Global Humanized Monoclonal Antibody Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Type (2021-2032)
  15. 4.2.3 Global Humanized Monoclonal Antibody Drugs Sales Value Share by Type (2021-2032)
5 Humanized Monoclonal Antibody Drugs Market by Application
  1. 5.1 Humanized Monoclonal Antibody Drugs Application Introduction
  2. 5.1.1 Cancers
  3. 5.1.2 Inflammatory Condition
  4. 5.1.3 Autoimmune Diseases
  5. 5.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Application
  6. 5.2.1 Global Humanized Monoclonal Antibody Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Humanized Monoclonal Antibody Drugs Sales Value Share by Application (2021-2032)
6 Humanized Monoclonal Antibody Drugs Regional Value Analysis
  1. 6.1 Global Humanized Monoclonal Antibody Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Humanized Monoclonal Antibody Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Humanized Monoclonal Antibody Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Humanized Monoclonal Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Humanized Monoclonal Antibody Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Humanized Monoclonal Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Humanized Monoclonal Antibody Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Humanized Monoclonal Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Humanized Monoclonal Antibody Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Humanized Monoclonal Antibody Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Humanized Monoclonal Antibody Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Humanized Monoclonal Antibody Drugs Sales Value Share by Country, 2025 VS 2032
7 Humanized Monoclonal Antibody Drugs Country-level Value Analysis
  1. 7.1 Global Humanized Monoclonal Antibody Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Humanized Monoclonal Antibody Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Humanized Monoclonal Antibody Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Humanized Monoclonal Antibody Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Humanized Monoclonal Antibody Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Humanized Monoclonal Antibody Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent Bio
  2. 8.1.1 Innovent Bio Company Information
  3. 8.1.2 Innovent Bio Business Overview
  4. 8.1.3 Innovent Bio Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Bio Humanized Monoclonal Antibody Drugs Product Portfolio
  6. 8.1.5 Innovent Bio Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Humanized Monoclonal Antibody Drugs Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Humanized Monoclonal Antibody Drugs Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Sun Pharmaceutical
  20. 8.4.1 Sun Pharmaceutical Company Information
  21. 8.4.2 Sun Pharmaceutical Business Overview
  22. 8.4.3 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sun Pharmaceutical Humanized Monoclonal Antibody Drugs Product Portfolio
  24. 8.4.5 Sun Pharmaceutical Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Humanized Monoclonal Antibody Drugs Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Qilu Pharma
  32. 8.6.1 Qilu Pharma Company Information
  33. 8.6.2 Qilu Pharma Business Overview
  34. 8.6.3 Qilu Pharma Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Qilu Pharma Humanized Monoclonal Antibody Drugs Product Portfolio
  36. 8.6.5 Qilu Pharma Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Humanized Monoclonal Antibody Drugs Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Merck & Co
  44. 8.8.1 Merck & Co Company Information
  45. 8.8.2 Merck & Co Business Overview
  46. 8.8.3 Merck & Co Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck & Co Humanized Monoclonal Antibody Drugs Product Portfolio
  48. 8.8.5 Merck & Co Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Humanized Monoclonal Antibody Drugs Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Eli Lilly & Co
  56. 8.10.1 Eli Lilly & Co Company Information
  57. 8.10.2 Eli Lilly & Co Business Overview
  58. 8.10.3 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly & Co Humanized Monoclonal Antibody Drugs Product Portfolio
  60. 8.10.5 Eli Lilly & Co Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Humanized Monoclonal Antibody Drugs Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Beigene
  68. 8.12.1 Beigene Company Information
  69. 8.12.2 Beigene Business Overview
  70. 8.12.3 Beigene Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Beigene Humanized Monoclonal Antibody Drugs Product Portfolio
  72. 8.12.5 Beigene Recent Developments
  73. 8.13 GlaxoSmithKline
  74. 8.13.1 GlaxoSmithKline Company Information
  75. 8.13.2 GlaxoSmithKline Business Overview
  76. 8.13.3 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 GlaxoSmithKline Humanized Monoclonal Antibody Drugs Product Portfolio
  78. 8.13.5 GlaxoSmithKline Recent Developments
  79. 8.14 Biogen
  80. 8.14.1 Biogen Company Information
  81. 8.14.2 Biogen Business Overview
  82. 8.14.3 Biogen Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Biogen Humanized Monoclonal Antibody Drugs Product Portfolio
  84. 8.14.5 Biogen Recent Developments
  85. 8.15 AbbVie
  86. 8.15.1 AbbVie Company Information
  87. 8.15.2 AbbVie Business Overview
  88. 8.15.3 AbbVie Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AbbVie Humanized Monoclonal Antibody Drugs Product Portfolio
  90. 8.15.5 AbbVie Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Humanized Monoclonal Antibody Drugs Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 UCB
  98. 8.17.1 UCB Company Information
  99. 8.17.2 UCB Business Overview
  100. 8.17.3 UCB Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 UCB Humanized Monoclonal Antibody Drugs Product Portfolio
  102. 8.17.5 UCB Recent Developments
  103. 8.18 Gilead Sciences
  104. 8.18.1 Gilead Sciences Company Information
  105. 8.18.2 Gilead Sciences Business Overview
  106. 8.18.3 Gilead Sciences Humanized Monoclonal Antibody Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gilead Sciences Humanized Monoclonal Antibody Drugs Product Portfolio
  108. 8.18.5 Gilead Sciences Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst